Claim Denial Rate by Insurance Company: A Comparison

Key takeaways

• Published denial rates vary widely because sources count initial adjudications and final dispositions differently.
• A high denial rate with high appeal overturns is a workflow problem, while a low rate with poor appeal success hides quiet write-offs.
• Weight each payer's denial rate by its share of your claims before comparing headline numbers or negotiating contracts.
• Neurology practices face specific denial drivers like prior authorization for imaging and Botox, plus E&M level documentation scrutiny.
• Track your own denial reasons by payer monthly to find revenue leaks and build leverage for contract renegotiations.

The claim denial rate by insurance company varies widely across major US payers, and published figures range from roughly 5% to over 15% depending on who counted what. This guide compares insurer-level rates side by side, explains why the numbers disagree, and shows what they hide about denial reasons and appeal outcomes that actually affect your AR aging. Use an AR aging report to see how unpaid balances move through each aging bucket.

What is the claim denial rate by insurance company, and where do the published numbers come from?

A claim denial rate is the percentage of submitted claims an insurer rejects, whether in full or for payment adjustment. It is usually reported two ways: the initial denial rate on first submission, and the final denial rate after appeals, which is typically far lower because many denials are recoverable. For a practice watching AR aging, the gap between the two is where most of the recoverable money sits.

Initial denial rate vs final denial rate after appeal

Initial rates measure payer friction and clean-claim quality. Final rates measure what survived appeal. A payer with a 20% initial rate and a 2% final rate behaves very differently from one that simply pays clean claims, so never compare the two figures as if they were the same metric.

Who publishes denial data and how often

The main public sources are payer transparency reports, hospital billing studies, and analyses of the Transparency in Coverage machine-readable files. KFF's health costs research includes the most-cited comparison of in-network denial rates by insurer across large payers, and it is updated irregularly rather than quarterly. Limitations: most datasets exclude small practices, mix specialties, and rarely break out denial reasons, so a neurology group's own payer mix will not match the averages.

How do denial rates compare across major health insurers like UnitedHealthcare, and why do sources disagree?

Normalized denial rate comparison table with methodology notes

Published figures for the same insurer routinely differ by double digits, because each source counts differently: initial adjudication vs. final disposition, all claim lines vs. all claims, and provider-submitted vs. clearinghouse-aggregated data. The table below is illustrative, showing the pattern practices see across sources rather than citable figures; another section of this article carries the primary sources.

Why UnitedHealthcare denial rate figures vary by source

The same UnitedHealthcare number can be quoted anywhere from roughly half to well over double, depending on whether the source measures claims denied on first pass or after appeals, and whether it reports by claim or by dollar value. A denial reversed on appeal is real work but not real lost revenue, yet some sources count it in the headline rate.

Medicare Advantage vs commercial vs traditional Medicare

Medicare Advantage sits between the two: it inherits Medicare's coverage rules but adds prior authorization and payer-specific edits that traditional Medicare does not apply. For a neurology practice, that difference shows up in your AR aging and your prior authorization queue, not in the payer's published rate. Tracking your own denial reasons by payer, as covered in our DeepCura comparison, matters more than any industry average.

Why do raw denial rates by company mislead without denial-reason and appeal-outcome data?

Two payers, same denial rate, opposite revenue outcomes

Payer A denies 10% of claims and your biller overturns 80% on first appeal. Payer B denies 10% and you write most of them off because the appeal is unwinnable or not worth the labor. Same published rate, opposite cash outcomes. ProPublica's Claim Denied project shows exactly this gap: insurer-level denial data paired with appeal overturn rates, where some plans overturn a large share of appealed claims. The raw rate tells you how often the fight starts, not who wins it.

A high denial rate with high overturn success is a workflow problem: your front end is losing winnable fights, and the fix is documentation, coding, and appeal discipline. A low denial rate with poor appeal success may hide quiet write-offs, where staff stop contesting because the payer's process makes appeals uneconomic. That is payer friction wearing a flattering statistic.

What appeal overturn rates add to the picture

Overturn rates tell you whether denial volume is noise or signal. If a payer reverses most appeals, denials are largely process artifacts you can engineer away with cleaner SOAP notes and tighter E&M support. If reversals are rare, the denial rate itself is the real cost, and it belongs in your payer-mix and contract conversations. Compare both numbers side by side at Scryber's payer comparison before you assume a payer's headline rate reflects what your neurology practice will actually collect.

Which claim denial reasons drive the differences between insurers?

Denial reason categories are fairly standard across payers: missing prior authorization, coding mismatch, eligibility, medical necessity, and timely filing. Insurers differ in how strictly they enforce each one, which is why the same claim can pass at one payer and bounce at another.

Prior authorization denials in neurology

Neurology hits prior authorization harder than most specialties. EEG, imaging, Botox for migraine and spasticity, and infusion drugs all routinely require it, and each payer maintains its own criteria and turnaround rules. A missing or expired auth is often unappealable, so prevention is the only real fix.

Coding and E&M level denials

Payers scrub E&M levels against documentation, and a neurological exam with cranial nerves and localization findings can support a higher level only if it is documented completely. Undercoding from thin notes costs you quietly; mismatched or unsupported levels get denied loudly. Tools like Scryber (compared with Heidi here) aim to capture exam detail fully enough that the billed level matches the note.

Eligibility, medical necessity, and timely filing

Eligibility denials are cheap to prevent with front-end checks but common when coverage lapses mid-treatment. Medical necessity denials cluster around repeat testing and off-label use. Timely filing is the least forgivable: miss the window and the money is gone, which is why AR aging discipline matters at every payer, not just the strictest one.

How should practices interpret a health insurance claim denial rate when choosing payers or negotiating contracts?

Normalize first. A 12% denial rate from a payer covering 40% of your panel hurts differently than 18% from one covering 5%. Weight each payer's rate by its share of your claims, then compare weighted figures, not headline numbers.

Next, filter denial reasons by your specialty. Prior authorization failures on imaging and longitudinal disease tracking visits behave differently than generic medical-necessity denials, and a payer's overall rate hides that. KFF's analysis of Medicare Advantage insurer-reported data shows denial rates vary widely across large insurers, which is why reason-level detail matters more than the topline.

Questions to ask a payer rep before signing

Ask for the denial reasons most common for neurology codes, the overturn rate on first-level appeals, and average days to payment. A payer with a high rate but fast, frequent overturns may outperform one with a low rate and slow payment.

Using your own denial data in contract talks

Bring your AR aging and denial breakdowns to the table. Payers negotiate against leverage, not anecdotes; showing a specific denial pattern by E&M level gives you a concrete ask. Dropping a payer reflexively can cost more than fixing the workflow — tools like Scryber exist for that, as shown in the Scryber vs Marvix comparison.

What can providers do to reduce denials regardless of the insurer's denial rate?

You cannot control a payer's rules, but four levers sit inside your practice: eligibility checks, prior authorization, documentation quality, and denial tracking.

Front-end fixes: eligibility and prior authorization

Run eligibility verification before the visit, not on the day of, so coverage lapses surface while the patient can still be rescheduled. For neurology, prior authorization is the bigger leak: imaging, Botox for chronic migraine, and infusion visits all carry auth requirements that vary by payer. A single missed auth turns a fully documented, medically necessary visit into a write-off.

Documentation that survives the denial review

Your note has to support the billed E&M level on its own. That means a localized neurological exam with cranial nerve findings, not "neuro exam normal," and an assessment that ties each diagnosis to the plan. This is not about upcoding; it is about capturing the work you already did. If a reviewer cannot see medical necessity in the note, the denial stands regardless of the insurer.

Tracking denial reasons by payer in your own AR

Tag every denial by reason code and payer, then review the pattern monthly against your AR aging. A rising denial rate on one contract is leverage in renegotiation.

How often are insurer denial rates updated, and where can you verify the latest figures?

There is no single refresh date. CMS releases Medicare Advantage and payer transparency files on its own schedule, ProPublica's Claim Denied project updates when it publishes new insurer data, and KFF revises its analyses as surveys land. Most stale blog numbers trace back to one snapshot of the Experian Health denial index, which tracks denial reasons across payers via Experian Health's State of Claims research.

A five-minute verification checklist for any denial statistic

Check the data year, not the publication year. Check whether the figure is initial denials or final write-offs. Check the denominator: claims, dollars, or encounters. Check whether it covers all payers or one plan. If the source names none of these, treat the number as marketing.

Where does denial visibility fit in a neurology practice's revenue workflow?

From SOAP note to final payment collected

A payer's denial rate is an output. Your input is the encounter itself: whether the neurological exam is documented at the level billed, whether localization and longitudinal disease tracking support the E&M level, and whether undercoding is quietly leaking revenue you already earned. Scryber works on that input side, capturing the visit and producing specialty-specific documentation for neurology, then following the encounter through to final payment collected so you can see where money stalls. With a 60-day free trial, then $85 per user per month, it is priced for a 1-10 provider practice where the P&L is yours.

What Scryber does not do

It does not file appeals, manage payer contracts, or replace your billing service. If your denial problem is eligibility or prior authorization workflow, Scryber gives you visibility, not a fix.

FAQ

Which insurance company denies the most claims?

Published comparisons put UnitedHealthcare at the high end for commercial payers. Anthem and Elevance land mid-to-high, while Aetna, Cigna, and Humana sit mid-range. Because sources count initial versus final denials differently, treat any ranking as a pattern rather than a precise ordering.

What is UnitedHealthcare's claim denial rate?

There is no single reliable number. The same UnitedHealthcare figure gets quoted anywhere from half to more than double depending on whether the source measures first-pass denials or final dispositions, and whether it counts claims or dollars. Denials reversed on appeal are real work but not lost revenue.

What percentage of denied claims are successfully appealed?

It varies enormously by payer and plan. ProPublica's Claim Denied project shows some plans reverse a large share of appealed claims while others reverse few. A payer that overturns most appeals presents a fixable workflow problem, while one that rarely does makes denials a genuine cost.

Do Medicare Advantage plans deny more claims than traditional Medicare?

Yes, generally. Traditional Medicare has a low initial denial rate and few soft denials. Medicare Advantage inherits Medicare's coverage rules but adds prior authorization and payer-specific edits traditional Medicare does not apply, causing denial rates to vary widely across large insurers.

How do I find my practice's denial rate by payer?

Pull it from your own AR data. Tag every denial by reason code and payer, then review the pattern monthly against your AR aging. Weight each payer's rate by its share of your claims before comparing. Your clearinghouse or billing system usually reports this, and your figures will not match published averages.